3 Groundbreaking Projects, 1 Winner of $100,000, You Decide
The BRIght Futures Prize supports Brigham and Women’s investigators as they work to answer provocative questions in medicine.
Now in its sixth year, the competition allows voters from the public to determine the winner of the competition’s $100,000 prize.
Learn more about how these three finalists aim to translate scientific discoveries into clinical therapies.
Break the Shake: Ultrasound Treatment for Epilepsy
Ellen Bubrick, MD, Neurologist, Division of Epilepsy
“We want to bring low-intensity, focused ultrasound to patients who are suffering from epileptic seizures. This noninvasive technique works by mechanical disruption of brain networks to treat the brain cells causing the seizures. This new form of ultrasound technology has not yet been offered to patients with epilepsy. We want to conduct a clinical trial to test this option as a treatment for patients who do not respond to medications.” -- Dr. Ellen Bubrick
Learn more about Dr. Bubrick’s project below and cast your vote at brightfuturesprize.org.
Ready, Aim, Fire: Destroy Brain Cancer
Choi-Fong Cho, PhD, Neuroscientist, Department of Neurosurgery
“We have developed a unique molecule that can cross the blood-brain barrier, as well as identify and home in on brain cancer cells. This allows us to target only the tumor cells without harming healthy tissue. Our research could help us develop the next generation of therapeutics to extend the lives of patients with advanced brain cancer, as well as improve the quality of life of the patients and their families. Ultimately, we aim to advance precision medicine in neuro-oncology and abolish brain cancer in the future.” -- Dr. Choi-Fong Cho
Surgery in a Pill: Reversing Type 2 Diabetes
Yuhan Lee, PhD, Materials Scientist, Division of Biomedical Engineering
“Diabetes is recognized as a global epidemic affecting 450 million people worldwide, with this number estimated to increase to 640 million by 2040. While many medications are available, fewer than half of patients who take them achieve appropriate blood sugar control. More challenging, three out of four patients who have diabetes live in low- and middle-income countries where access to some of the newer, more expensive mediations is limited. LuCI provides an alternative, more affordable therapeutic option that can be taken orally, and without systemic absorption, while providing the benefits of a major surgery.” -- Yuhan Lee, PhD